Ramiro Sanchez - Dec 15, 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Dec 15, 2023
Transactions value $
-$236,293
Form type
4
Date filed
12/19/2023, 04:15 PM
Previous filing
Dec 11, 2023
Next filing
Dec 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise $74.1K +7.5K $9.88 7.5K Dec 15, 2023 Direct
transaction CERE Common Stock Sale -$310K -7.5K -100% $41.39 0 Dec 15, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Options Exercise $0 -7.5K -5.73% $0.00 123K Dec 15, 2023 Common Stock 7.5K $9.88 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.385 to $41.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 50% of the shares subject to this option vested and became exercisable on October 28, 2022, with the remainder vesting in two (2) equal annual installments thereafter.